Could a simple pill shield HAE patients from Procedure-Triggered attacks?

NCT ID NCT07654829

Not yet recruiting Disease control Sponsor: KalVista Pharmaceuticals, Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This trial tests whether the drug sebetralstat can prevent swelling attacks in people with hereditary angioedema (HAE) when taken before a medical procedure. Participants aged 12 and older with HAE type I or II will take sebetralstat just before their scheduled procedure. The main goal is to see if the drug prevents an HAE attack within 24 hours after the procedure starts.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sebetralstat (KVD900)
What this could lead to: If effective, sebetralstat could offer a simple pill to prevent dangerous swelling attacks triggered by medical procedures.
What could go wrong: This is an open-label trial without a placebo, so results may be less reliable. The drug may not prevent all attacks, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hereditary angioedema type 1 hereditary angioedema type 2 hereditary angioedema prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEREDITARY ANGIOEDEMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

KalVista Investigative Site

Colorado Springs, Colorado, 80907, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.